Authors
Tony Bottiglieri
Anglia Ruskin University
Laia Rodriguez
Universidad Complutense de Madrid
Rafael Gonzalez Del Solar
Universitat Autonoma de Barcelona
Abstract
© 2015 American Association for Cancer Research. In animal models of hepatocellular carcinoma, deficiency of S-adenosylmethionine increased the risk of HCC whereas administration of SAMe reduced HCC. The aim of this trial was to determine whether oral SAMe administration to patients with hepatitis C cirrhosis would decrease serum a-fetoprotein level, a biomarker of HCC risk in hepatitis C. This was a prospective, randomized, placebo-controlled, double-blind trial of SAMe, up to 2.4 g/d, for 24 weeks as compared with placebo among subjects with hepatitis C cirrhosis and a mildly elevated serum AFP. Primary outcome was change in AFP between baseline and week 24. Secondary outcomes included changes in routine tests of liver function and injury, other biomarkers of HCC risk, SAMe metabolites, markers of oxidative stress, and quality of life. One hundred ten subjects were randomized and 87 completed treatment. There was no difference in the change in AFP during 24 weeks among subjects receiving SAMe as compared with placebo. Changes in markers of liver function, liver injury, and hepatitis C viral level were not significantly different between groups. Similarly, SAMe did not change markers of oxidative stress or serum glutathione level. SAMe blood level increased significantly among subjects receiving SAMe. Changes in quality of life did not differ between groups. Overall, this trial did not find that SAMe treatment improved serum AFP in subjects with advanced hepatitis C cirrhosis and a mildly elevated AFP. SAMe did not improve tests of liver function or injury or markers of oxidative stress or antioxidant potential.
Keywords No keywords specified (fix it)
Categories No categories specified
(categorize this paper)
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 61,008
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

No references found.

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

Historique des recherches sur la différenciation des Hépatites A & B.Jean-Luc Meyer - 1992 - History and Philosophy of the Life Sciences 14 (1):93 - 111.
Consent to Open Label Extension Studies: Some Ethical Issues.P. Wainwright - 2002 - Journal of Medical Ethics 28 (6):373-376.

Analytics

Added to PP index
2017-03-08

Total views
2 ( #1,392,019 of 2,439,465 )

Recent downloads (6 months)
2 ( #282,588 of 2,439,465 )

How can I increase my downloads?

Downloads

Sorry, there are not enough data points to plot this chart.

My notes